Drupal.behaviors.print = function(context) {window.print();window.close();}>

DxS' TheraScreen Gets Canadian OK

July 13, 2009

DxS' TheraScreen Gets Canadian OK

By a GenomeWeb staff reporter

Health Canada granted a marketing license for DxS' TheraScreen: K-RAS Mutation Kit as a companion diagnostic for Amgen's colorectal cancer therapy panitumumab (Vectibix).

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories